Hostname: page-component-5db58dd55d-jnbmb Total loading time: 0 Render date: 2026-05-27T01:44:39.306Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science: (February 2008)

Published online by Cambridge University Press:  01 May 2008

R Sutherland
R Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Journals Watch
Information
Breast Cancer Online , Volume 11 , Issue 5 , May 2008 , e10
Copyright
Copyright © Cambridge University Press 2008

References

1.Arnes, JB, Collett, K, Akslen, LA. Lesson of the month – independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008; 52: 370–380.CrossRefGoogle Scholar
2.Averous, J, Fonseca, BD, Proud, CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2008; 27: 1106–1113.CrossRefGoogle ScholarPubMed
3.Bergarnaschi, A, Tagliabue, E, Sorlie, T, Naurne, B, Triulzi, T, Orlandi, R, Russnes, HG, Nesland, JM, Tammi, R, Auvinen, P, Kosma, VM, Menard, S, Borresen-Dale, AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214: 357–367.CrossRefGoogle Scholar
4.Blank, EW, Wong, PY, Lakshmanaswamy, R, Guzman, R, Nandi, S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci USA 2008; 105: 3527–3532.CrossRefGoogle ScholarPubMed
5.Fritah, A, Saucier, C, De Wever, O, Bracke, M, Bieche, I, Lidereau, R, Gespach, C, Drouot, S, Redeuilh, G, Sabbah, M. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 2008; 28: 1114–1123.CrossRefGoogle ScholarPubMed
6.Holick, CN, Newcomb, PA, Trentham-Dietz, A, Titus-Ernstoff, L, Bersch, AJ, Stampfer, MJ, Baron, JA, Egan, KM, Willett, WC. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 379–386.CrossRefGoogle ScholarPubMed
7.Iorns, E, Turner, NC, Elliott, R, Syed, N, Garrone, O, Gasco, M, Tutt, ANJ, Crook, T, Lord, CJ, Ashworth, A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008; 13: 91–104.CrossRefGoogle ScholarPubMed
8.Kouros-Mehr, H, Bechis, SK, Slorach, EM, Littlepage, LE, Egeblad, M, Ewald, AJ, Pai, SY, Ho, IC, Werb, Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141–152.CrossRefGoogle Scholar
9.Lagadec, C, Adriaenssens, E, Toillon, RA, Chopin, V, Romon, R, Van Coppenolle, F, Hondermarck, H, Le Bourhis, X. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 2008; 27: 1472–1477.CrossRefGoogle ScholarPubMed
10.Levy, N, Tatomer, D, Herber, CB, Zhao, XY, Tang, H, Sargeant, T, Ball, LJ, Summers, J, Speed, TP, Leitman, DC. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 2008; 22: 287–303.CrossRefGoogle Scholar
11.Liu, HL, Liu, Y, Zhang, JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Therap 2008; 7: 263–270.CrossRefGoogle ScholarPubMed
12.Liu, S, Ginestier, C, Charafe-Jauffret, E, Foco, H, Kleer, CG, Merajver, SD, Dontu, G, Wicha, MS. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105: 1680–1685.CrossRefGoogle ScholarPubMed
13.Maekawa, T, Sano, Y, Shinagawa, T, Rahman, Z, Sakuma, T, Nomura, S, Licht, JD, Ishii, S. ATF-2 controls transcription of Maspin and GADD45 α genes independently from p53 to suppress mammary tumors. Oncogene 2008; 27: 1045–1054.CrossRefGoogle ScholarPubMed
14.Meijer, D, Jansen, M, Look, M, Ruigrok-Ritstier, K, Staveren, I, Sieuwerts, A, Agthoven, T, Foekens, J, Dorssers, L, Berns, E. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res Treat 2008; 10.1007/s10549-008-9934-3.Google ScholarPubMed
15.Parker, BS, Ciocca, DR, Bidwell, BN, Gago, FE, Fanelli, MA, George, J, Slavin, JL, Moller, A, Steel, R, Pouliot, N, Eckhardt, BL, Henderson, MA, Anderson, RL. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol 2008; 214: 337–346.CrossRefGoogle ScholarPubMed
16.Potapova, A, Hoffman, AM, Godwin, AK, Al-Saleem, T, Cairns, P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008; 68: 998–1002.CrossRefGoogle ScholarPubMed
17.Rahman, M, Davis, S, Pumphrey, J, Bao, J, Nau, M, Meltzer, P, Lipkowitz, S. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2008; 10.1007/s10549-008-9924-5.Google ScholarPubMed
18.Reineke, EL, Lam, M, Liu, O, Liu, Y, Stanya, KJ, Chang, KS, Means, AR, Kao, HY. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol 2008; 28: 997–1006.CrossRefGoogle Scholar
19.Sakai, W, Swisher, EM, Karlan, BY, Agarwal, MK, Higgins, J, Friedman, C, Villegas, E, Jacquemont, C, Farrugia, DJ, Couch, FJ, Urban, N, Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116–1120.CrossRefGoogle ScholarPubMed
20.Sarrio, D, Rodriguez-Pinilla, SM, Hardisson, D, Cano, A, Moreno-Bueno, G, Palacios, J. Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68: 989–997.CrossRefGoogle Scholar
21.Srinivasan, D, Sims, JT, Plattner, R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008; 27: 1095–1105.CrossRefGoogle ScholarPubMed
22.Subbaramaiah, K, Hudis, C, Chang, SH, Hla, T, Dannenberg, AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells – evidence of a BRCA1 and p300 exchange. J Biol Chem 2008; 283: 3433–3444.CrossRefGoogle ScholarPubMed
23.Thangasamy, A, Rogge, J, Ammanamanchi, S. Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells. J Biol Chem 2008; 283: 5335–5343.CrossRefGoogle ScholarPubMed
24.Travis, RC, Allen, NE, Appleby, PN, Spencer, EA, Roddam, AW, Key, TJ. A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer 2008; 122: 705–710.CrossRefGoogle ScholarPubMed
25.Voduc, D, Cheang, M, Nielsen, T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008; 17: 365–373.CrossRefGoogle Scholar
26.Wendt, MK, Cooper, AN, Dwinell, MB. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 2008; 27: 1461–1471.CrossRefGoogle ScholarPubMed
27.Williams, C, Edvardsson, K, Lewandowski, SA, Strom, A, Gustafsson, JA. A genome-wide study of the repressive effects of estrogen receptor β on estrogen receptor α signaling in breast cancer cells. Oncogene 2008; 27: 1019–1032.CrossRefGoogle ScholarPubMed